Why Viaderma Inc (OTCMKTS:VDRM) Shares Popped Higher Again


Viaderma Inc (OTCMKTS:VDRM) shares rose 38.60% on Friday to $0.00790 and were flat in after-hours trading. Share prices have been trading in a 52-week range of $0.00 to $0.02. The company has a market cap of $2.73 million at 200.32 million shares outstanding.

Viaderma Inc is a pharmaceutical company focused on bringing new products to the pharmaceutical industry through research and development. It licenses and sells products in fields of medicine ranging from infectious diseases to stem-cell therapy. Its products are applied topically using a delivery system technology and are are used within the over-the-counter market.

In addition to the primary plan of developing and selling new products to the market, Viaderma Inc is exploring the possibility of licensing the technology to other pharmaceutical companies. It has products in development in various fields, including topical antibiotics TetraStem, topical anti-viral product Viralcur for genital herpes, anti-fungal products for onychomycocis OnyPro, hair loss prevention product HairGain, skin cancer therapies Cantrile, and a topical stem cell therapy product TetraStem Plus.

Following its announcement of Patent Pending use of its innovative transdermal system for the delivery of Calanoids and Tetrahydrocannabinol for the treatment of several diseases in December last year, it shared that several patients have had significant treatment success with the use of its innovative transdermal system for the delivery of its FDA-registered drug, Viabecline. Early this year, Viaderma Inc CEO Dr. Christopher Otiko filed a patent application with the USPTO for its proprietary innovative transdermal delivery system.

Apart from that, the company has also signed licensing and distribution agreements with two Pharmaceuticals companies for its FDA registered drug, Viabecline, which is an OTC topical antibiotic that is capable of significant healing results in just 10 days of treatment by combing a common FDA-approved antibiotic, Tetracycline, through the company’s proprietary transdermal delivery system.

ViaDerma is ready to move forward in 2017. We are taking an aggressive growth path this year with product licensing deals that we expect to increase our revenue growth. We have many opportunities with the use of our proprietary transdermal delivery system for specialized treatments and continuing studies. We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community,” said Dr. Christopher Otiko.

He added that Viaderma Inc is also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido.

On the stock’s daily time frame, it can be seen that another surge in volumes took place at the start of this year as investor interest picked up. This followed the rally in December, thanks to the company’s latest announcements. Further progress in its patent applications and clinical studies could lead to a more sustained climb, possibly resulting to a break past the $0.01 barrier and a climb to the highs near $0.02. On the other hand, lack of company updates or negative results in its pursuits could send the stock price back to its 52-week lows once more.

DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.